anti-TNFRSF10C (TNFRSF10C) Antikörper

Bezeichnung:
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy Without An Intracellular Domain Antikörper (TNFRSF10C)
Auf www.antikoerper-online.de finden Sie aktuell 150 Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy Without An Intracellular Domain (TNFRSF10C) Antikörper von 19 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen TNFRSF10C Proteine (11) und TNFRSF10C Kits (10) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 174 TNFRSF10C Produkte verfügbar.
Synonyme:
CD263, DCR1, DCR1-TNFR, LIT, TNFRSF10C, TRAIL-R3, TRAILR3, TRID
Alle Antikörper anzeigen Gen GeneID UniProt
TNFRSF10C 8794 O14798
TNFRSF10C    
TNFRSF10C    

Alle Spezies anzeigen

Weitere Synonyme anzeigen

Meistgesuchte Reaktivitäten zu anti-TNFRSF10C (TNFRSF10C) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human TNFRSF10C Antikörper:

anti-Mouse (Murine) TNFRSF10C Antikörper:

anti-Rat (Rattus) TNFRSF10C Antikörper:

Alle verfügbaren anti-TNFRSF10C Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-TNFRSF10C Antikörper

  1. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN4899000 : Barbarotto, Corallini, Rimondi, Fadda, Mischiati, Grill, Vaccarezza, Celeghini: Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. in Journal of cellular biochemistry 2008 (PubMed)
    Zeige alle 11 Referenzen für 4899000

  2. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN4895308 : Gojo, Tan, Fang, Sadowska, Lapidus, Baer, Carrier, Beumer, Anyang, Srivastava, Espinoza-Delgado, Ross: Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. in Clinical cancer research : an official journal of the American Association for Cancer Research 2013 (PubMed)
    Zeige alle 7 Referenzen für 4895308

  3. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN238512 : Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006 (PubMed)
    Zeige alle 5 Referenzen für 238512

  4. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN487315 : Deligezer, Dalay: Expression of the TRAIL receptors in blood mononuclear cells in leukemia. in Pathology oncology research : POR 2007 (PubMed)
    Zeige alle 5 Referenzen für 487315

  5. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN487314 : Clancy, Mruk, Archer, Woelfel, Mongkolsapaya, Screaton, Lenardo, Chan: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. in Proceedings of the National Academy of Sciences of the United States of America 2005 (PubMed)
    Zeige alle 5 Referenzen für 487314

  6. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN301991 : Falschlehner, Emmerich, Gerlach, Walczak: TRAIL signalling: decisions between life and death. in The international journal of biochemistry & cell biology 2007 (PubMed)
    Zeige alle 4 Referenzen für 301991

  7. Human Monoclonal TNFRSF10C Primary Antibody für ICC, FACS - ABIN1169230 : Wachter, Sprick, Hausmann, Kerstan, McPherson, Stassi, Bröcker, Walczak, Leverkus: cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. in The Journal of biological chemistry 2004 (PubMed)
    Zeige alle 4 Referenzen für 1169230

  8. Human Monoclonal TNFRSF10C Primary Antibody für FACS - ABIN1106171 : Baritaki, Katsman, Chatterjee, Yeung, Spandidos, Bonavida: Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. in Journal of immunology (Baltimore, Md. : 1950) 2007 (PubMed)
    Zeige alle 2 Referenzen für 1106171

  9. Human Polyclonal TNFRSF10C Primary Antibody für WB - ABIN2774599 : Inagaki, Morimura, Tang, Akutagawa, Kida: Tryptophol induces death receptor (DR) 5-mediated apoptosis in U937 cells. in Bioscience, biotechnology, and biochemistry 2007 (PubMed)

Weitere Antikörper gegen TNFRSF10C Interaktionspartner

Human Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy Without An Intracellular Domain (TNFRSF10C) Interaktionspartner

  1. High levels of TRAIL-R3 and CCR-2 expression in tumor epithelial cells identified patients with early breast cancer with poor outcomes.

  2. Results identified epigenetic inactivation of TNFRSF10C and TNFRSF10D (zeige TNFRSF10D Antikörper) in majority of cervical cancer cases.

  3. DcR1 levels in serum sample which were significantly lower in AMD (zeige AMD1 Antikörper) patients.

  4. DcR1 upregulation mediates temozolomide resistance.

  5. The membrane expression of the TRAIL receptors DR4 (zeige HLADRB4 Antikörper), DR5 (zeige TNFRSF10B Antikörper), DcR1 and DcR2 (zeige CCR6 Antikörper) is greater in normal endometrium than endometrioid adenocarcinoma (EAC (zeige CYLD Antikörper)). The level of the receptors in EAC (zeige CYLD Antikörper) is not dependent on grading and staging and does not predict survival.

  6. the results presented here claim for a relevant impact of aberrant methylation of decoy receptors in melanoma and allow to understand how the silencing of DcR1 and DcR2 (zeige CCR6 Antikörper) is related to melanomagenesis.

  7. GATA4 (zeige GATA4 Antikörper) and DcR1 promoter hypermethylation is tumor specific event in glioblastoma but they promoter methylation cannot be considered as a prognostic marker of glioblastoma survival.

  8. Primary EOC is associated to a lower TRAIL-R3 expression.

  9. Data show that about 20% of AML (zeige RUNX1 Antikörper) patients highly expressed decoy receptor TRAIL-R3, which was strongly correlated to a shortened overall survival.

  10. Decoy receptors DcR1 and DcR2 (zeige CCR6 Antikörper) on CD8 (zeige CD8A Antikörper)+ T cells, but not on CD4 (zeige CD4 Antikörper)-positive T cells, are positively correlated with patients' DAS (zeige ube3a Antikörper) scores.

TNFRSF10C Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.

Alternative names and synonyms associated with TNFRSF10C

  • tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain (TNFRSF10C) Antikörper
  • CD263 Antikörper
  • DCR1 Antikörper
  • DCR1-TNFR Antikörper
  • LIT Antikörper
  • TNFRSF10C Antikörper
  • TRAIL-R3 Antikörper
  • TRAILR3 Antikörper
  • TRID Antikörper

Bezeichner auf Proteinebene für TNFRSF10C

TNF-related apoptosis-inducing ligand receptor 3 , antagonist decoy receptor for TRAIL/Apo-2L , cytotoxic TRAIL receptor-3 , decoy TRAIL receptor without death domain , decoy receptor 1 , lymphocyte inhibitor of TRAIL , tumor necrosis factor receptor superfamily member 10C , tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain

GENE ID SPEZIES
8794 Homo sapiens
472713 Pan troglodytes
Ausgewählte Anbieter für anti-TNFRSF10C (TNFRSF10C) Antikörper
Haben Sie etwas anderes gesucht?